研究実績

Hashimoto D, Satoi S, Yamaki S, Nakayama S, Shibata N, Matsumura K, Miyazaki H, Matsui Y, Tsybulskyi D, Sang NT, Ikeura T, Kanai M, Sekimoto M.,2025/01,Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal Adenocarcinoma,Annals of surgical oncology,Ann Surg Oncol,32(1):517-528,10.1245/s10434-024-16361-y,39433718

Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, Hirano H, Ohtsubo K, Ohta T, Oki E, Nishina T, Yasui H, Kawakami H, Esaki T, Machida N, Doi A, Boku S, Kudo T, Yamamoto Y, Kanazawa A, Denda T, Goto M, Iida N, Ozaki H, Shibuki T, Imai M, Fujisawa T, Bando H, Naito Y, Yoshino T.,2024/07,Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors,BJC reports,BJC Rep,2(1):54,10.1038/s44276-024-00073-7,39516322

Kato C, Iizuka-Ohashi M, Honda M, Konishi E, Yokota I, Boku S, Mizuta N, Morita M, Sakaguchi K, Taguchi T, Watanabe M, Naoi Y.,2024/12,Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer,Biochimica et biophysica acta. Molecular basis of disease,Biochim Biophys Acta Mol Basis Dis,1870(8):167458,10.1016/j.bbadis.2024.167458,39128642

Takahiro Nakayama, Naoki Niikura, Takashi Yamanaka, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Hironori Nomura, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata, Akihiko Shimomura1, Yuri Ozaki, Shuji Sakai, Daisuke Takiguchi, Takehiko Takata, Armin Bastanfard, Kazuhito Shiosakai, Junji Tsurutani,2024/11,Trastuzumab deruxtecan for the treatment of patients with HER2‑positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET‑BM),Breast cancer,Breast Cancer,31(6):1167-1175,10.1007/s12282-024-01614-1,39133378

Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T.,2024/11,The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine,Cancer discovery,Cancer Discov,14(11):2243-2261,10.1158/2159-8290.CD-24-0206,39023403

Ikoma T, Matsumoto T, Boku S, Motoki Y, Kinoshita H, Kosaka H, Kaibori M, Inoue K, Sekimoto M, Fujisawa T, Iwai H, Naganuma M, Tanizaki H, Hisamatsu Y, Okada H, Kurata T.,2024/05,Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study,Cancer immunology, immunotherapy : CII,Cancer Immunol Immunother,73(7):126,10.1007/s00262-024-03707-4,38733406

Kanai M.,2025/02,Challenges and Opportunities for the Clinical Application of the Combination of Immune-Checkpoint Inhibitors and Radiation Therapy in the Treatment of Advanced Pancreatic Cancer,Cancers,Cancers (Basel),17(4):606,10.3390/cancers17040606,40002201

Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y.,2024/09,Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer,Clinical cancer research,Clin Cancer Res,30(18):4167-4178,10.1158/1078-0432.CCR-24-1023,39163021

Honma Y, Monden N, Yamazaki K, Kano S, Satake H, Kadowaki S, Utsumi Y, Nakatogawa T, Takano R, Fujii K, Koroki Y, Aoyama J, Ouchi S, Ogawa T, McCarthy S, Brookman-May SD, Mundle S, Li J, Thaper D, Nagao T, Tada Y.,2024/08,Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU,Clinical cancer research,Clin Cancer Res,30(16):3416-3427,10.1158/1078-0432.CCR-24-0455,38940667

Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, Tanaka K, Hayashi H, Onoe T, Asada Y, Yamazaki T, Nose T, Ohata S, Nagatani Y, Kimbara S, Funakoshi Y, Teshima M, Shinomiya H, Minami H.,2024/06,A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody,ESMO open,ESMO open,9(6):103476,10.1016/j.esmoop.2024.103476,38833968

Nakao T, Shindo T, Takakura H, Narita T, Ise-Nakao Y, Akiyama S, Iizumi Y, Boku S, Watanabe M, Sakai T, Shimizu S, Yamada M, Sowa Y, Mutoh M.,2025/02,Trametinib Suppresses the Stimulated T Cells Through G1 Arrest and Apoptosis,European journal of immunology,Eur J Immunol,55(2):e202350667,10.1002/eji.202350667,39989249

Kataoka K, Ouchi A, Suwa Y, Hirano H, Yamaguchi T, Takamizawa Y, Hanaoka M, Iguchi K, Boku S, Nagata K, Koyama T, Shimada Y, Inomata M, Sano Y, Mizusawa J, Hamaguchi T, Takii Y, Tsukamoto S, Takashima A, Kanemitsu Y; JCOG Colorectal Cancer Study Group.,2024/06,Localized colorectal cancer database integrating 4 randomized controlled trials; (JCOG2310A),European journal of surgical oncology,Eur J Surg Oncol,50(6):108354,10.1016/j.ejso.2024.108354,38657376

Ando K, Satake H, Shimokawa M, Yasui H, Negoro Y, Kinjo T, Kizaki J, Baba K, Orita H, Hirata K, Sakamoto S, Makiyama A, Saeki H, Tsuji A, Baba H, Oki E.,2025/03,A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer,International journal of clinical oncology,Int J Clin Oncol,30(3):514-523,10.1007/s10147-025-02701-9,39891883

Hamada M, Matsumi Y, Inada R, Matsumoto T, Kita M, Boku S, Kurokawa H, Tsuta K.,2025/03,MRI navigation surgery for T4b rectal cancer using multiple minimally invasive surgical approaches,International journal of colorectal disease,Int J Colorectal Dis,40(1):66,10.1007/s00384-025-04838-5,40085244

Sano Y, Kanai M, Morizane C, Sasaki K, Yoshimura M, Ito Y, Furuse J, Ozaka M, Fukuda H, Ueno M; Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group.,2024/11,Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE),Japanese journal of clinical oncology,Jpn J Clin Oncol,54(11):1214-1218,10.1093/jjco/hyae084,38941345

Shimada S, Yamada T, Minamoto A, Matsukawa M, Yabe I, Tada H, Oda K, Ueki A, Higashigawa S, Morikawa M, Sato Y, Hirasawa A, Ogawa M, Kondo T, Yoshioka M, Kanai M, Muto M, Kosugi S.,2025/01,Nationwide survey of the secondary findings in cancer genomic profiling: survey including liquid biopsy,Journal of human genetics,J Hum Genet,70(1):33-40,10.1038/s10038-024-01294-x,39289525

Kataoka K, Yamada T, Shiozawa M, Takase N, Ito K, Yamazaki K, Watanabe J, Kudo T, Suto T, Matsumoto T, Murata K, Suwa Y, Boku S, Yasui H, Matsuhashi N, Maeda A, Sugimoto K, Matsumoto Y, Yokota M, Fredebohm J, Mori K, Ikeda M.,2024/04,Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies,Journal of the anus, rectum and colon,J Anus Rectum Colon,8(2):132-136,10.23922/jarc.2023-051,38689780

Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, Yoshino T, Kato T, Tsuji A.,2024/09,QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC,Med (New York, N.Y.),Med,5(9):1164-1177,10.1016/j.medj.2024.05.012,38901425

Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsuhashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, Yoshino T.,2025/01,Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors,Nature medicine,Nat Med,31(1):165-175,10.1038/s41591-024-03244-8,39284955

Kobayashi S, Wada H, Sakai D, Baba H, Kanai M, Kamachi H, Takayama T, Ueno M, Takahashi M, Sho M, Yoshimura K, Hatano E, Nagano H, & Ioka T,2024/10,Impact of Tumor Shrinkage Pattern with Biweekly Triplet Gemcitabine+Cisplatin+S-1 Regimen for Biliary Tract Cancers: Implications for Neoadjuvant Therapy from the Data of KHBO1401 (KHBO1401-1A Study),Oncology,Oncology,102(6):447-456,10.1159/000533669,38048759

Shibuki T, Ikeda M, Yokoyama M, Sano Y, Furuse J, Kobayashi S, Ohba A, Todaka A, Horie Y, Shioji K, Kanai M, Nishina T, Kumamoto Y, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Miwa H, Ozaka M, Ueno M.,2025/03,Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407,Pancreatology,Pancreatology,25(2):275-283,10.1016/j.pan.2025.02.005,39984379

Maruo M, Ikeura T, Takaori A, Ikeda M, Nakamaru K, Ito T, Masuda M, Mitsuyama T, Nakayama S, Shimatani M, Takaoka M, Shibata N, Boku S, Yasuda T, Miyazaki H, Matsumura K, Yamaki S, Hashimoto D, Satoi S, Naganuma M.,2024/08,Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal adenocarcinoma,Pancreatology,Pancreatology,24(5):787-795,10.1016/j.pan.2024.06.001,38871559

Shiraishi K, Okada M, Yamamoto S, Matsubara Y, Masuishi T, Shimozaki K, Yamamoto Y, Hirose S, Sugiyama K, Furuta M, Machida N, Takahashi N, Yoshii T, Kito Y, Tsuzuki T, Boku S, Tsuchihashi K, Sugaya A, Takayama T, Komori A, Mitani S, Matsumoto T, Nishimura T, Hirata K.,2025/03,The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma,Scientific reports,Sci Rep,15(1):8031,10.1038/s41598-025-92657-7,40055515

Shibuki T, Ikeda M, Yokoyama M, Sano Y, Furuse J, Kobayashi S, Ohba A, Todaka A, Horie Y, Shioji K, Kanai M, Nishina T, Kumamoto Y, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Miwa H, Ozaka M, & Ueno M.,2025/02,Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors,The Oncologist,Oncologist,30(2):oyae113,10.1093/oncolo/oyae113,38821532

https://kmuaa.kmu.ac.jp/kmuhp/GsApp

金井雅史 AMED「薬剤耐性と副作用の克服を目指した多発性骨髄腫に対するプロドラッグ型抗がん薬TBP1901の前臨床研究」 科研費「オキサリプラチンの至適投与法に関する研究」   朴将源 AMED「患者由来がん幹細胞培養を基盤とした革新的個別化医療開発」